Redeye comments on Active Biotech's Q3 report. During the quarter, Active Biotech reported laquinimod concentrations in the vitreous segment of the eye and a rights issue. The rights issue can fund the the company through the completion of the laquinimod's biodistribution study in 2025, which may position it for a licensing deal.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/